nucleoside analogues for the treatment of influenza: history and experience
https://doi.org/10.22625/2072-6732-2019-11-3-20-26
Abstract
Aim. In this study we retrospectively evaluated the clinical effectiveness and safety of nucleoside analogues (Triazavirin© and ribavirin) with that of oseltamivir for treating moderate severe influenza in adults.
Materials and methods. We have used data from 191 health records of patients with moderate severe PCR confirmed influenza A and B. Control group included 57 patients treated with oseltamivir, comparison groups – 53 and 81 patients, who received Triazavirin© and ribavirin accordingly. We compared infectious intoxication syndrome duration, fever duration, duration of acute rhinitis, acute pharyngitis, acute laryngitis, acute tracheitis, acute bronchitis, cough duration as well as pneumonia occurrence.
Results. No statistically significant difference in the duration of developed syndromes in Triazavirin©-treated group and oseltamivir-treated group were observed. We have noticed that fever duration had been significantly longer in ribavirin group compared to control group (4,1±2,22 days vs. 3,1±1,94 days, p<0,05) as well as more frequent pneumonia occurrence (1,2% vs. 0,0%, p>0,05).
Conclusion. New nucleoside analogue Triazavirin© showed good efficacy and safety profile in adult patients with influenza. This fact provides the opportunity to recommend it for treatment of influenza along with neuraminidase inhibitors.
About the Authors
K. V. Kasianenko
Military Medical Academy named after S.M. Kirov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
N. I. Lvov
Military Medical Academy named after S.M. Kirov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
O. V. Maltsev
Military Medical Academy named after S.M. Kirov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
K. V. Zhdanov
Military Medical Academy named after S.M. Kirov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Lvov N.I. et al. Zhurnal infektologii. 2014; 6 (3): P.62–79 (in Russian).
2. Influenza virus infections in humans October 2018 [Internet]. – Available from: http://www.who.int/influenza/human_animal_interface/virology_laboratories_and_vaccines/influenza_virus_infections_humans _Oct_18.pdf. – (cited 12.11.2018).
3. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro / J.T. Nguyen [et al.] // PLoS One. – 2010. – №5 (22). – Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009332 – (cited 12.11.2018).
4. Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms / S. Boivin [et al.] // The Journal of biological chemistry. – 2010. – №285 (37). – P.28411-28417.
5. Stevaert, A. The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design / A. Stevaert, L. Naesens // Medicinal research reviews. – 2016. – №36 (6). – P. 1127-1173.
6. Crotty, S. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? / S. Crotty, C. Cameron, R. Andino // Journal of Molecular Medicine. – 2002. – №80 (2). – P.86-95.
7. Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1, 2 , 4-triazole--3-carboxamide (ribavirin) / L.B. Allen [et al.] // The Journal of medicinal chemistry. – 1978. – №21 (8). – P.742-746.
8. Chill, D.W Inhibition of measles virus replication and enhancement of cellular DNA synthesis in vero cells by ribavirin, an antiviral and antineoplastic drug / D.W Chill, P.B. Johnston // Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. – 1975. – №8 (2). – P.67-72.
9. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A / A. Cohen [et al.] // The Journal of infectious diseases. – 1976. – №133. – P. 114-120.
10. Togo, Y. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus / Y. Togo, E.A. McCracken // The Journal of infectious diseases. – 1976. – №133. – P.109-113.
11. Double blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers / C.R. Magnussen [et al.] // Antimicrobial Agents and chemotherapy. – 1977. – №12 (4). – P.498-502.
12. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection / C.B. Smith [et al.] // The Journal of infectious diseases. – 1980. – №141 (5). – P.548-554.
13. Salido-Rengell, F. Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole- -3-carboxamide (ribavirin) in a doubleblind study during an outbreak of influenza / F. Salido-Rengell, H. Nasser-Quinones, B. Briseno-Garcia // Annals of New York Academy of Sciences. – 1977. – №284. – P. 272-277.
14. Oral ribavirin treatment of influenza A and B / D.S. Stein [et al.] // Antimicrobial Agents and chemotherapy. – 1987. – №31 (8). – P.1285-1287.
15. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83(H1N1) and B/Texas/1/84 / B.E. Gilbert [et al.] // Antimicrobial Agents and chemotherapy. – 1985. – №27 (3). – P.309-313.
16. Ribavirin small-particle aerosol treatment of influenza / V. Knight [et al.] // Lancet (London, England). – 1981. – №2 (8253). – P. 945-949.
17. Ribavirin aerosol treatment of influenza B virus infection / H.W. McClung [et al.] // JAMA. – 1983. – №249 (19). – P.2671-2674.
18. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol / S.Z. Wilson [et al.] // Antimicrobial Agents and chemotherapy. – 1984. – №26 (2). – P. 200-203.
19. Ribavirin small-particle-aerosol treatment of influenza B virus infection / D.I. Bernstein [et al.] // Antimicrobial Agents and chemotherapy. – 1988. – №32 (5). – P.761-764.
20. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double blind, multicenter, placebo-controlled trial / W.J. Rodriguez [et al.] // The Journal of pediatrics. – 1994. – №125 (1). – P.129-135.
21. Gripp i drugie ostrye respiratornye zabolevaniya: ukazaniya po diagnostike, lecheniyu i profilaktike v Vooruzhennyh Silah Rossijskoj Federacii. – M., 1999. – 64 s. (in Russian).
22. Diagnostika, lechenie i profilaktika ostryh respiratornyh zabolevanij i grippa v Vooruzhennyh Silah Rossijskoj Federacii. Metodicheskie rekomendacii. – M., 2018. –95 s. (in Russian).
23. Favipiravir (T-705), a novel viral RNA polymerase inhibitor / Y. Furuta [et al.] // Antiviral research. – 2013. – №100 (2). – P. 446-454.
24. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 (H1N1) viruses / M. Sleepman [et al.] // Antimicrobial Agents and chemotherapy. – 2010. – №54 (6). – P. 2517-2524.
25. Favipiravir: a new medication for the Ebola virus disease pandemic / T. Nagata [et al.] // Disaster of medicine and public health preparedness. – 2015. – №9 (1). – P.79-81.
26. Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins / V.L. Rusinov [et al.] // Chemistry of Heterocyclic Compounds. – 2015. – №51 (3). – P.275–280.
27. Loginova S.Y. et al. Antibiotiki i himioterapiya. 2007; 52:.18-20 (in Russian).
28. Sologub T.V. et al. Infekcionnye bolezni. 2017:15 (3):.40-47 (in Russian).
29. Gripp u vzroslyh. Federal’nye klinicheskie rekomendacii. – Krasnodar, 2018. – 90 s.
30. Tihonova E.P et al. Kazanskij medicinskij zhurnal 2018; 99 (2):.215-223 (in Russian).
31. Verevshchikov V.K. et al. Antibiotiki i himioterapiya 2018; 63:.3-6 (in Russian).
Review
For citations:
Kasianenko K.V., Lvov N.I., Maltsev O.V., Zhdanov K.V. nucleoside analogues for the treatment of influenza: history and experience. Journal Infectology. 2019;11(3):20-26. (In Russ.) https://doi.org/10.22625/2072-6732-2019-11-3-20-26
Views:
4324
.png)
.png)
Email this article 